We will be presenting tomorrow at the Stifel 2024 Virtual Targeted Oncology Forum at 11:30 AM ET. A live webcast of the virtual presentation will be available. Read more: brnw.ch/21wIPiC

Our team was founded by industry veterans who have played important roles in discovering and developing various findings in #oncology and other disease areas. Thank you to the doctors who evaluate and treat our areas of focus. #NationalDoctorsDay

Our CEO, Steve Worland, PhD, spoke with Benjamin Burnett, PhD, of Stifel, about our product candidate for the treatment of patients with non-small cell #LungCancer . Listen to the full chat here: brnw.ch/21wIjv6 $EFTR

This #PatientSafetyAwarenessWeek , we emphasize the importance of patient safety during #ClinicalTrials . At eFFECTOR, our passion is using the best science to develop better medicines to treat cancer – including by conducting clinical trials. Learn more: brnw.ch/21wHLne

Ahead of anticipated data from our Phase 2b KICKSTART study, learn about our lead Selective Translation Regulator Inhibitor (STRI) for patients with non-small cell lung cancer ( #NSCLC ). Read more on our website: brnw.ch/21wHA8H $EFTR

This snapshot from our recent Virtual R&D Day showcases the importance of addressing the #UnmetNeed in treatment for those with cancer. Listen now, and see more about the potential impact of our technology, here: brnw.ch/21wHp64 $EFTR

At our recent Virtual R&D Day, Dr. Kevin Kalinsky discussed how our Selective Translation Regulator Inhibitor (STRI) shows promise in endocrine receptor-positive #BreastCancer as a potential combination therapy. Stay tuned for more insights! $EFTR

Our Chief Medical Officer, Dr. Doug Warner, brings passion and expertise to our leadership team with his experience in solid tumor immune-oncology and pathway inhibitor development programs. Read more about Doug and our team, here: brnw.ch/21wGYiM

#DYK more than 1 in 5 people will be diagnosed with cancer in their lifetime? That is why this #WorldCancerDay and beyond, we are steadfast in our mission to deprive cancer of what it needs to give patients what they need. Read about our oncology pipeline: brnw.ch/21wGGUd

Our President & CEO, Steve Worland, will be presenting at the Chemical Biology Consortium Symposium, co-hosted by National Cancer Institute and Sanford Burnham Prebys, today at 2:10pm. His presentation will cover our novel approach to #CancerTherapy , focused on STRIs. Learn more: brnw.ch/21wGydU

The eFFECTOR leadership team has a deep understanding of translation regulation biology and oncology drug development. We asked our CEO, Steve Worland why he’s proud to lead our team as we pioneer the development of first in class #oncology drugs.

Join us January 24 at 4:30 pm ET for our virtual R&D Day with presentations by our management team & Kevin Kalinsky, MD, MS. The event will feature a summary of development progress for tomivosertib & zotatifin and a preview of 2024 milestones. Register now: brnw.ch/21wG7tJ

At #SABCS2023 , we presented data from our #ClinicalTrial evaluating our potential new treatment for those living with ER+ metastatic breast cancer. Learn more about the Phase 2a expansion data here: brnw.ch/21wFXtx

Will you be attending @JPMorgan’s 42nd Annual #Healthcare Conference this year? The eFFECTOR team is looking forward to meeting with investors in San Francisco. If you’re interested in speaking with us about our #CancerResearch , contact us today: brnw.ch/21wFKTZ #JPM24

eFFECTOR has had a wonderful year filled with connection. Looking to 2024, we are excited for what is to come in advancing our pipeline for those living with #cancer .

Our Chief Medical Officer, Douglas Warner, MD, provides an overview of our potential product candidate for ER+/HER2- #BreastCancer , and the current status of our Phase 1/2 dose escalation and expansion study in an interview with Pharmacy Times. brnw.ch/21wFvK9

#HappyHolidays from all of us at eFFECTOR! We're immensely thankful for the unwavering support of our mission to develop innovative treatments for #cancer . Together, we enhance our commitment to a healthier future.

We are excited to share our Phase 2a data from the #ClinicalTrial evaluating our Selective Translation Regulator Inhibitor (STRI) in people living with #BreastCancer . Learn more about our data and SABCS presentation from #SABCS2023 : brnw.ch/21wF9gg

#ICYMI , eFFECTOR has been selected as the BioTech Breakthrough ”Therapeutic Solution of the Year.” We are honored to have been recognized for our solutions to cancer treatment. To learn more about our pipeline, see here: brnw.ch/21wF2vA

Selective Translation Regulator Inhibitors (STRIs) represent a fundamentally different approach to #cancer therapy in comparison to other treatments. Our CEO, Steve Worland, Ph.D., recently connected with Drug Target Review to provide insights on our STRIs: drugtargetreview.com/article/112485…